BiotechTV - News

The CEO of Blueprint (up to the acquisition) discusses the company's success factors, and being led to immunology by the science. Plus, why she believes an oral pill that is disease modifying, like Fulcrum is trying to develop, is strongly needed for the sickle cell patient community.

He walks us through the design, build, test, learn model that is the foundation of Generate's approach to drug development.

He welcomes us to Benchtalk 2025, which had more than 800 scientists register this year, and describes how AI and other computational advances are allowing scientists to focus on increasing the speed and reducing the cost of R&D.

He describes the science behind FORCE, which combines an antigen-binding fragment, a linker and, a payload. The company's DMD program will have a key trial readout before the end of this year, and DM1 will follow in 2026. Both programs could be filed for AA in 2026 with positive data.

Co-Founder & CEO Laurent Martinot discusses the raise, and the need for more accessible sleep health care. Plus, previewing a clinical trial of its device that will read out shortly.

CEO Craig Marshall describes how the company's "metra" device pumps blood through donor organs (currently livers) in order to extend the amount of time they can be transplanted safely.

CEO Ros Deegan discusses the deal and the path to getting there, and she highlights some of OMass' other programs the company is driving forward alone, including an MC2 antagonist. Plus, the company's unique expertise in the use of mass spec.

He discusses the rally biotech has had of late, and that was boosted by Pfizer's deal with the White House. Plus, how interest rates, employment, and other factors are affecting the broader economy, and might impact biotech.

Ben Zeskind describes the company's 9 month follow-up for atebimetinib + mGnP, which showed 86% overall survival and 53% progression free survival.

He shares his thoughts on Soleno, Sarepta, Lexeo, Enanta, Crinetics, Vertex, Xenon, and more.

He discusses the clinical profile of IBTROZI, how the launch is going, and describes other work the company is doing in precision medicine. Plus, his take on the biotech environment currently.

CEO Rafiq Hasan describes to BiotechTV's Amy Brown during an interivew in London how this program works, and he compares and contrasts it to more traditional therapies that are on the market currently. Plus, and overview of Complement's other programs and operations.

Co-Founder & CEO Graham Dempsey describes the different between Nav1.7 and 1.8, and why he thinks having an ASO approach will succeed in 1.7 where small molecules have not. Plus, an epilepsy program, and what it is like being an earlier stage company today.

Co-Founder & CEO Nabanita Nawar describes the need for tackle HDAC6 with better chemistry. Plus, what it is like being a biotech startup in Canada today.

Co-Founder and CEO Aaron Edwards describes the rational behind this approach, as opposed charging the cells with cytokines or removing their brakes. He also explains why KiraGen is looking abroad to do its first clinical trials.

CEO Amir Nashat, who has decades of experience in biotech at Polaris Partners, describes the work Soufflé has been doing to catalogue often rare targets and design ligands that carry payloads to them such as siRNAs and ASOs. The company plans to be in the clinic next year and is starting out with muscle conditions.

The company recently received a grant from the Michael J. Fox Foundation to work on Parkinson's, and has existing partnerships with companies such as Novo and Charles River.

Chief Executive Officer Jack O'Meara, who previously founded Ochre Bio in the RNA space, describes the potential benefits of using brain shuttles and why the time is right for this approach. Plus, the company's business model and what to expect next.

CEO Jay Luly and CMO Scott Rottinghaus describe today's data, which was focused on high risk adults. They explain how safety and efficacy were measured, and what the learnings were from a handful of endpoints. Plus, Enanta's earlier stage I&I programs targeting KIT and STAT6.

He discussed how current technologies are making healthcare more effecient today, how new technologies are opening new markets, and how the practice of medicine might be changed in the process.

Connor Landgraf shows us the product and describes recent data the company compiled in the UK showing the benefits of using this digital and AI enhanced device over a traditional stethoscope.

He describes the raise and the trial, which is an umbrella study that will test products against three different mutations. Plus, work on vaccines and a non-oncology cell therapy program, and partnership opportunities.

CEO Per Andersson walks us through the benefits of designing kinase inhibitors this way, which should not be affected by the pH of the stomach. He shows us the unique manufacturing equipment, and walks us through a pipeline that includes dasatinib, nilotinib, axitinib, and cabozantinib.

CEO Nicklas Westerholm walks us through the condition, which is an X-chromosome linked rare disease that affects men, and he describes how the launch is going in Europe, and plans for an FDA meeting.

CEO Christer Ahlberg describes the shortcomings of today's medicines, and why he believes a P-CAB is the answer. This therapy originated at AstraZeneca, though Cinclus owns it outright today, and is in a phase 3 that just started.